Use of Granulocyte-Macrophage Colony-Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML

  • E. Estey
  • H. Kantarjian
  • S. O’Brien
  • M. Beran
  • K. McCredie
  • C. Koller
  • J. Schachner
  • M. Keating
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

A body of in vitro evidence suggests that use of granulocyte-macrophage colony-stimulating factor (GM-CSF) might increase the in vivo sensitivity of leukemic myeloblasts to daunorubicin-cytosine arabinoside (ara-C) chemotherapy [1–4]. If so, administration of GM-CSF prior to and during administration of daunorubicin/ara-C might overcome the resistance to therapy that is characteristic of acute myeloid leukemia (AML). This resistance is most obvious in patients with abnormalities of chromosomes 5, 7, (−5, −7, 5q-, 7q-) who frequently fail even to enter initial complete remission (CR), but it is also a major problem in patients with other aneuploidies (except INV(16), t (15; 17), or t (8; 21)), or with a normal karyotype or insufficient metaphases for analysis [5].While the majority of these patients enter CR, their remissions rarely last more than 2 years.

Keywords

Leukemia Anemia Oncol Resis Sine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cannistra SA, Groshek P, Griffin JD (1989) Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis of chronic myeloid leukemia. Leukemia 3: 328–334PubMedGoogle Scholar
  2. 2.
    Hiddemann W, Kiehl M, Schleyer E, Woermann B, Zuehlsdorf M, Buechner T (1989) Stimulating effect of GM-CSF and IL-3 on the metabolism and cytotoxic activity of cytosine arabinoside in leukemia blasts from patients with acute myeloid leukemia. Blood 74 (Suppl 1): 230aGoogle Scholar
  3. 3.
    Santini V, Noater K, Delwel R, Loewenberg B (1990) Susceptibility of acute myeloid leukemia cells from clinically resistant and sensi tive patient to daunomycin: assessment in vitro after stimulation with colony stimulating factors. Leuk Res 14: 377–380PubMedCrossRefGoogle Scholar
  4. 4.
    Tafuri A, Andreeff M (1990) Kinetic rationale for cytokine-induced recruitment of myelo blastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4: 826–835PubMedGoogle Scholar
  5. 5.
    Keating M, Cork A, Broach Y, Smith T, Walters R, McCredie K, Trujillo J, Freireich E (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res: 119–133Google Scholar
  6. 6.
    Cassileth PA, Harrington DP, Hines JD, Oken MM, Maza JJ, McGlave P, O’Connell MJ (1988) Maintenance chemotherapy prolongs remission duration in adult acute none lymphocytic leukemia. J Clin Oncol 6: 583–587PubMedGoogle Scholar
  7. 7.
    Keating M, Smith T, Kantarjian H, Cork A, Walters R, Trujillo J, McCredie K, Gehan E, Freireich E (1988) Cytogenetic pattern in acute myelogenous leukemia: a major repro ducible determinant of outcome. Leukemia 2: 403–412PubMedGoogle Scholar
  8. 8.
    Estey E, Smith T, Keating M, McCredie K, Gehan E, Freireich E (1989) Prediction of survival during induction therapy in patients with newly diagnosed acute myelogenous leukemia. Leukemia 3: 257–263PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • E. Estey
    • 1
  • H. Kantarjian
    • 1
  • S. O’Brien
    • 1
  • M. Beran
    • 1
  • K. McCredie
    • 1
  • C. Koller
    • 1
  • J. Schachner
    • 1
  • M. Keating
    • 1
  1. 1.Department of HematologyUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations